Can inflammatory musculoskeletal disorders restrict walking and raise inflammatory markers?

Inflammatory musculoskeletal disease can affect both physical function and systemic inflammatory testing, although the strength and pattern of these findings vary by diagnosis and individual.

Functional effects

• In rheumatoid arthritis (RA), the most directly studied condition in this group, gait impairment and reduced lower-limb motion are well established. A meta-analysis of 36 inflammatory-arthritis studies found slower walking, shorter stride length, lower cadence, lower ankle power, and longer double-limb support versus healthy controls.
• A systematic review of 78 RA gait studies likewise found slower gait, prolonged double-support time, avoidance of extreme joint positions, and reduced hip, knee, and ankle range of motion. Pain, synovitis/swelling, structural damage, muscle dysfunction, and reduced conditioning can each contribute.
• Functional effects are not identical across disorders: reduced walking speed has been reported in psoriatic arthritis and gout, while this was not found in the included ankylosing-spondylitis studies.

Systemic inflammatory markers and mechanism

• Inflammatory activity can raise CRP and ESR. In RA, CRP contributes to composite disease-activity assessment; in axial spondyloarthritis, elevated CRP is associated with imaging inflammation and structural progression.
• Mechanistically, IL-6—augmented by IL-1β—drives hepatic CRP synthesis. Thus, CRP reflects systemic acute-phase signaling rather than proving inflammation in a particular joint, tendon, muscle, or connective tissue site.
• Marker results are incomplete: CRP can be normal despite clinically active RA, and only about 40–50% of people with ankylosing spondylitis have elevated CRP or ESR. CRP alone is often unsuitable for assessing psoriatic-arthritis activity or treatment response.

Clinical interpretation

• CRP and ESR support, but do not diagnose, inflammatory musculoskeletal disease. Infection, malignancy, sterile tissue injury, and other inflammatory states can also elevate them.

Bottom line

• Inflammatory musculoskeletal disorders can restrict walking and range of motion and may elevate systemic inflammatory markers, but mobility assessment and laboratory results require diagnosis-specific, clinical interpretation.